{"slideshow_credits": null, "snippet": "An experimental drug for eczema relieved severity of symptoms in 85 percent of those who took it. A drug for psoriasis cut severity of symptoms in as many as 82 percent of those who took it.", "abstract": "Papers published in New England Journal of Medicine find that new drugs that block highly specific parts of immune system are showing promise in treating eczema and psoriasis.", "section_name": "Business Day", "print_page": null, "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/07/10/business/drugs-show-promise-in-treating-eczema-and-psoriasis-in-trials.html", "lead_paragraph": "An experimental drug for eczema relieved severity of symptoms in 85 percent of those who took it. A drug for psoriasis cut severity of symptoms in as many as 82 percent of those who took it.", "headline": {"seo": "Early Findings in Drugs From Sanofi and Regeneron", "main": "In Small Trials, 2 Drugs Go Far in Soothing Symptoms of Eczema and Psoriasis", "print_headline": "In Small Trials, 2 Drugs Go Far in Soothing Symptoms of Eczema and Psoriasis"}, "_id": "53bdba0838f0d86b6274e63e", "word_count": "1039", "multimedia": [{"height": 126, "url": "images/2014/07/10/business/10skins-pic1/10skins-pic1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/07/10/business/10skins-pic1/10skins-pic1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 900, "url": "images/2014/07/10/business/10skins-pic1/10skins-pic1-articleLarge.jpg", "legacy": {"xlarge": "images/2014/07/10/business/10skins-pic1/10skins-pic1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "900"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/07/10/business/10skins-pic1/10skins-pic1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/07/10/business/10skins-pic1/10skins-pic1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-07-10T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Eczema", "name": "subject", "is_major": "Y", "rank": "5"}, {"value": "Novartis AG", "name": "organizations", "is_major": "N", "rank": "7"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "6"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "New England Journal of Medicine", "name": "organizations", "is_major": "Y", "rank": "8"}, {"value": "Enbrel (Drug)", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "Skin", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Psoriasis", "name": "subject", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}